DTx Pharma

Please note: The information displayed on this page might be outdated.
DTx Pharma: Developer of an RNA-based therapeutics designed to aid in personalized treatment across most therapeutic areas. The company's technology enables efficient delivery of nucleic acid drugs to tissues throughout the body, enabling healthcare providers to deliver oligos in vivo at therapeutically relevant doses that work in many cell types including neurons, endothelial and T cells.
Based in...
US - Pacific
3210 Merryfield Row
San Diego, CA 92121
United States

Company Participants at Spring Private Company Showcase

Arthur Suckow
DTx Pharma, CEO
Dr. Suckow received his PhD from University of California, San Diego and has worked for Johnson & Johnson, AstraZeneca, where he co-founded and managed the biologics laboratory of over 30 scientists, and Regulus Therapeutics. Dr. Suckow’s extensive experience in lipid pharmacology includes advancing lipidated peptides into clinical development and taking small molecules targeting lipid receptors into clinical development.
Denise Bevers
DTx Pharma, COO
Ms. Bevers joined DTx as Chief Operating Officer in November 2020. She brings over 30 years of pharmaceutical and biotechnology industry experience to DTx, with significant drug development expertise and a history of building clinical, commercial and manufacturing teams. Prior to joining DTx, Ms. Bevers served as President & COO of Kindred Biosciences, a veterinary biopharmaceutical company that she co-founded in 2012. Previously, Ms. Bevers was President & Founding Partner of SD Scientific and held management positions at Elan Pharmaceuticals, SkyePharma, Quintiles, and Scripps Clinic and Research Foundation. Currently, Ms. Bevers serves on the Board of Directors of KindredBio, Hilltop Bio and on the Board of Trustees of the La Jolla Playhouse.